In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing Weeks af­ter Am­gen took a $2.7 bil­lion stake in BeiGene, the Bei­jing-based biotech has se­cured its first-ever FDA ap­proval for zanubru­ti­nib, a BTK in­hibitor, months ahead of sched­ule. BeiGene’s drug, brand­ed as Brukin­sa, has se­cured ac­cel­er­at­ed ap­proval for adult pa­tients with man­tle cell lym­phoma (MCL) — a typ­i­cal­ly ag­gres­sive, rare, form of blood can­cer — who have re­ceived at least one pri­or ther­a­py. The ap­proval is based on da­ta from pa­tients that were large­ly based out­side of the Unit­ed States. The main tri­al re­lied up­on in the mar­ket­ing ap­pli­ca­tion is a sin­gle-arm, 86-pa­tient tri­al, which showe...